Published in Lancet Oncol on September 01, 2013
MLN8237 in Head and Neck Cancer | NCT01540682
MLN8237 and Pazopanib in Combination for Solid Tumors | NCT01639911
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. J Transl Med (2015) 0.81
Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression. Mol Cancer Ther (2015) 0.79
Molecular aspects of prostate cancer with neuroendocrine differentiation. Chin J Cancer Res (2016) 0.78
Gene expression profiling via bioinformatics analysis reveals biomarkers in laryngeal squamous cell carcinoma. Mol Med Rep (2015) 0.77
Non-centrosomal TPX2-Dependent Regulation of the Aurora A Kinase: Functional Implications for Healthy and Pathological Cell Division. Front Oncol (2016) 0.77
The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism. Oncotarget (2014) 0.76
In vitro evaluation of a combination treatment involving anticancer agents and an aurora kinase B inhibitor. Oncol Lett (2016) 0.75
Opposing Effects of Inhibitors of Aurora-A and EGFR in Autosomal-Dominant Polycystic Kidney Disease. Front Oncol (2015) 0.75
C-X-C motif receptor 7 in gastrointestinal cancer. Oncol Lett (2015) 0.75
Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. Sci Rep (2017) 0.75
Kinase signaling and targeted therapy for primary myelofibrosis. Exp Hematol (2016) 0.75
Characterization of the Indirubin Derivative LDD970 as a Small Molecule Aurora Kinase A Inhibitor in Human Colorectal Cancer Cells. Immune Netw (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin (2012) 14.47
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
NCBI GEO: archive for functional genomics data sets--10 years on. Nucleic Acids Res (2010) 14.38
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst (2008) 12.77
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 11.86
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 8.66
Genevestigator v3: a reference expression database for the meta-analysis of transcriptomes. Adv Bioinformatics (2008) 8.36
The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol (2003) 8.32
Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell (2000) 6.81
HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell (2007) 6.50
The cellular geography of aurora kinases. Nat Rev Mol Cell Biol (2003) 6.40
Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell (1995) 5.56
Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol (2006) 4.66
Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J (2002) 4.54
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol (2010) 4.39
Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature (2008) 4.33
Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat Cell Biol (2003) 4.31
Aurora-A - a guardian of poles. Nat Rev Cancer (2005) 4.11
Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science (2008) 3.77
AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell (2003) 3.50
Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet (2003) 3.38
Sensing centromere tension: Aurora B and the regulation of kinetochore function. Trends Cell Biol (2010) 2.88
Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 2.88
Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell (2002) 2.56
The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome. Nat Cell Biol (2005) 2.52
Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther (2009) 2.37
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol (2005) 2.18
Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M transition. J Cell Sci (2004) 1.93
Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci (2012) 1.84
CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci (2009) 1.84
A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab (2012) 1.80
Centrosome maturation. Curr Top Dev Biol (2000) 1.72
Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci U S A (2012) 1.66
Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal (2010) 1.64
Plk1 regulates mitotic Aurora A function through betaTrCP-dependent degradation of hBora. Chromosoma (2008) 1.60
A telomere-dependent DNA damage checkpoint induced by prolonged mitotic arrest. Nat Struct Mol Biol (2012) 1.59
Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res (2012) 1.56
Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. Mol Cell Biol (2009) 1.51
Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res (2004) 1.44
Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst (1999) 1.44
Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab (2004) 1.36
Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res (2011) 1.30
Differential functions of the Aurora-B and Aurora-C kinases in mammalian spermatogenesis. Mol Endocrinol (2006) 1.30
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer (2012) 1.27
GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther (2009) 1.27
Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function. EMBO J (2002) 1.25
HEF1-aurora A interactions: points of dialog between the cell cycle and cell attachment signaling networks. Cell Cycle (2006) 1.25
Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene (2005) 1.22
Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene (2010) 1.19
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clin Cancer Res (2012) 1.17
Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck (2009) 1.17
Quantitative, fluorescence-based in-situ assessment of protein expression. Methods Mol Biol (2009) 1.16
The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front Biosci (Landmark Ed) (2012) 1.12
Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts. PLoS One (2011) 1.12
Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res (2007) 1.11
Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget (2011) 1.10
Pattern formation in centrosome assembly. Curr Opin Cell Biol (2012) 1.07
Constitutive phosphorylation of aurora-a on ser51 induces its stabilization and consequent overexpression in cancer. PLoS One (2007) 1.07
NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation. PLoS One (2011) 1.06
Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J Clin Pathol (2007) 1.05
Chromosome instability modulated by BMI1-AURKA signaling drives progression in head and neck cancer. Cancer Res (2012) 1.04
Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch (2007) 1.03
Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther (2008) 1.03
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res (2009) 1.01
Nuclear Survivin expression is correlated with malignant behaviors of head and neck cancer together with Aurora-B. Oral Oncol (2010) 1.01
Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene (2011) 0.98
The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther (2009) 0.97
Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9. Cancer Res (2010) 0.96
Aurora kinase inhibitors: identification and preclinical validation of their biomarkers. Expert Opin Ther Targets (2008) 0.96
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol (2009) 0.93
Effects of stable knockdown of Aurora kinase A on proliferation, migration, chromosomal instability, and expression of focal adhesion kinase and matrix metalloproteinase-2 in HEp-2 cells. Mol Cell Biochem (2011) 0.93
Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Sci Transl Med (2013) 0.92
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol (2010) 0.92
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. Cancer Res (2010) 0.92
PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther (2010) 0.91
High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer. Strahlenther Onkol (2012) 0.90
Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents? Cancer Biol Ther (2010) 0.89
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer (2011) 0.86
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol (2011) 0.86
Overexpression of Aurora-A promotes laryngeal cancer progression by enhancing invasive ability and chromosomal instability. Eur Arch Otorhinolaryngol (2011) 0.85
Oncogenic role of nuclear accumulated Aurora-A. Mol Carcinog (2009) 0.83
HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell (2007) 6.50
Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell (2005) 4.83
The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome. Nat Cell Biol (2005) 2.52
KRIT1 association with the integrin-binding protein ICAP-1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis. Hum Mol Genet (2002) 2.28
Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol (2010) 1.93
Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci (2012) 1.84
CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci (2009) 1.84
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) (2005) 1.80
Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal (2010) 1.64
Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol (2004) 1.54
Cell cycle-dependent ciliogenesis and cancer. Cancer Res (2008) 1.54
NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res (2009) 1.53
Increased recurrences using intensity-modulated radiation therapy in the postoperative setting. Am J Clin Oncol (2010) 1.52
Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci U S A (2002) 1.52
A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res (2007) 1.48
Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets (2007) 1.44
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol (2013) 1.42
Simian virus 40 large T antigen targets the spindle assembly checkpoint protein Bub1. Proc Natl Acad Sci U S A (2004) 1.42
Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2014) 1.39
Dissection of HEF1-dependent functions in motility and transcriptional regulation. J Cell Sci (2002) 1.29
Primary cilia and the cell cycle. Methods Cell Biol (2009) 1.28
HEF1-aurora A interactions: points of dialog between the cell cycle and cell attachment signaling networks. Cell Cycle (2006) 1.25
Deregulation of HEF1 impairs M-phase progression by disrupting the RhoA activation cycle. Mol Biol Cell (2006) 1.19
Calmodulin activation of Aurora-A kinase (AURKA) is required during ciliary disassembly and in mitosis. Mol Biol Cell (2012) 1.13
Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J (2003) 1.12
Aurora A kinase activity influences calcium signaling in kidney cells. J Cell Biol (2011) 1.10
Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res (2003) 1.10
Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray. Cancer Epidemiol Biomarkers Prev (2008) 1.09
Interdependence of cell attachment and cell cycle signaling. Curr Opin Cell Biol (2006) 1.08
A novel Cas family member, HEPL, regulates FAK and cell spreading. Mol Biol Cell (2008) 1.07
Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys (2003) 1.07
Targeting EGFR resistance networks in head and neck cancer. Cell Signal (2009) 1.07
The GDP exchange factor AND-34 is expressed in B cells, associates with HEF1, and activates Cdc42. J Immunol (2003) 1.06
A novel RING finger protein, human enhancer of invasion 10, alters mitotic progression through regulation of cyclin B levels. Mol Cell Biol (2003) 1.06
Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.06
NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation. PLoS One (2011) 1.06
The extracellular matrix and ciliary signaling. Curr Opin Cell Biol (2012) 1.03
Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol (2003) 1.02
Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin Cancer Res (2010) 1.02
Bimodal population or pathologist artifact? J Clin Oncol (2007) 1.00
The role of the cilium in normal and abnormal cell cycles: emphasis on renal cystic pathologies. Cell Mol Life Sci (2012) 0.99
Activation of p21-activated kinase 1-nuclear factor kappaB signaling by Kaposi's sarcoma-associated herpes virus G protein-coupled receptor during cellular transformation. Cancer Res (2003) 0.99
Significance of pathologic response to preoperative therapy in pancreatic cancer. Ann Surg Oncol (2011) 0.99
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics (2009) 0.98
Rapid calcium-dependent activation of Aurora-A kinase. Nat Commun (2010) 0.98
Molecular pathways: sterols and receptor signaling in cancer. Clin Cancer Res (2013) 0.97
Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets (2009) 0.96
Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9. Cancer Res (2010) 0.96
Detection of peptides, proteins, and drugs that selectively interact with protein targets. Genome Res (2002) 0.96
Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression. Thyroid (2013) 0.93
In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors. Mol Cancer Ther (2007) 0.92
Autoinhibited proteins as promising drug targets. J Cell Biochem (2004) 0.92
Regulation of cholesterol biosynthesis and cancer signaling. Curr Opin Pharmacol (2012) 0.91
Primary Sjögren's syndrome and deficiency of ICA69. Lancet (2002) 0.91
Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. Cancer Discov (2012) 0.90
Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease. Proc Natl Acad Sci U S A (2013) 0.90
Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma. Clin Cancer Res (2011) 0.90
Mucosal melanoma of the head and neck. J Natl Compr Canc Netw (2012) 0.89
Human enhancer of invasion-cluster, a coiled-coil protein required for passage through mitosis. Mol Cell Biol (2004) 0.89
Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents? Cancer Biol Ther (2010) 0.89
Network analysis identifies an HSP90-central hub susceptible in ovarian cancer. Clin Cancer Res (2013) 0.88
A 1.55 A resolution X-ray crystal structure of HEF2/ERH and insights into its transcriptional and cell-cycle interaction networks. Proteins (2007) 0.88
Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer. Cancer Biol Ther (2003) 0.88
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. J Gastrointest Cancer (2012) 0.88
The centrosomal kinase Plk1 localizes to the transition zone of primary cilia and induces phosphorylation of nephrocystin-1. PLoS One (2012) 0.86
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resist Updat (2011) 0.86
ICA69(null) nonobese diabetic mice develop diabetes, but resist disease acceleration by cyclophosphamide. J Immunol (2002) 0.86
Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer (2006) 0.86
Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. Hum Genet (2014) 0.84
Structure, stability, and function of hDim1 investigated by NMR, circular dichroism, and mutational analysis. Biochemistry (2003) 0.83
Dcas supports cell polarization and cell-cell adhesion complexes in development. PLoS One (2010) 0.83
p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primary. Head Neck (2014) 0.83
A gene expression system offering multiple levels of regulation: the Dual Drug Control (DDC) system. BMC Biotechnol (2004) 0.82
Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer (2005) 0.82
Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers. Clin Cancer Res (2013) 0.82
Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein. Mol Cell Biol (2007) 0.82